Internationale Partnersuche

Innovation & Technologie Angebot

Biomarkers for the diagnosis of pediatric B-cell acute lymphoblastic leukemia

Country of Origin: Spain
Reference Number: TOES20210625001
Publication Date: 25 June 2021

Summary

A Spanish university has developed two new biomarkers for the diagnosis of pediatric B-cell acute lymphoblastic leukemia. The technology makes it possible to recognize and evaluate patients who develop the disease and thus supports in therapeutic decision-making. The university is looking for partners interested in licensing this patented technology.

Description

Pediatric B-cell acute lymphoblastic leukemia (B-ALL) is the most common childhood malignancy that, characterized by its heterogeneity and aggressiveness, requires new targeted therapies. In recent years, this search has focused on the identification of non-coding Ribonucleic acid (ncRNA), crucial regulators of gene expression. Dysregulation of these long ncRNAs (lncRNAs) has been linked to numerous human diseases and is also associated with oncogenic or tumor suppressor phenotypes.



Given the absence of a clinically relevant lncRNA consensus signature for pediatric B-ALL, researchers at a Spanish University  have studied the lncRNA profiles of pediatric patients with this lymphoma, identifying two new biomarkers for the diagnosis, prognosis, prevention, improvement or alleviation in the treatment. 



This invention provides the use of lncRNA and mRNA as diagnostic biomarkers, whose method consists in the quantification of their expression levels from an isolated sample of the bone marrow of the individual. In this way, by comparing the amounts expressed, it is possible to obtain useful data for the diagnosis of pediatric B-ALL, facilitating therapeutic decision-making in these patients.



The university is looking for partners from pharmaceutical or biotechnology / health related companies interested in licensing this patented technology.

Advantages and Innovations

• Diagnostic biomarkers of pediatric B-cell acute lymphoblastic leukemia that allows the evaluation and identification of individuals with the disease.



• Support in the therapeutic strategy of patients with pediatric B-cell acute lymphoblastic leukemia: The use of these biomarkers could be used in therapeutic decision-making for patients with the desease. 



• No specific equipment is required. Quantification of biomarker expression can be carried out using a variety of currently popular techniques, generally common and accessible in laboratories in the field such as Reverse transcription polymerase chain reaction (RT-PCR), among others). 



• Simple method. The possibility of using a kit or device makes it easier to obtain useful data for the diagnosis and prognosis of this type of leukemia.

Stage Of Development

Under development/lab tested

Requested partner

The university is looking for partners from biotech / health / pharma related companies with experience in the use of biomarkers and/or  pediatric ALL-B diagnosis, interested in licensing this technology.

Kooperationsanfrage stellen